论文部分内容阅读
目的评价头孢克肟片治疗慢性细菌性前列腺炎的临床疗效和安全性。方法采用前瞻仰性随机平行对照临床研究,应用头孢克肟治疗慢性细菌性前列腺炎39例,并以司帕沙星治疗42例作对照。结果试验组治愈32例(82.1%),对照组治愈28例(66.7%)。试验组中未见任何不良反应,对照组中7例(16.7%),两组间比较治愈率、有效率差异无统计学意义(P>0.05),不良反应发生率差异有统计学意义(P<0.05)。结论头孢克肟治疗细菌性前列腺炎的临床疗效与对照组(司帕沙星组)相当,而不良反应则明显低于对照组,值得在临床上推广应用。
Objective To evaluate the clinical efficacy and safety of cefixime tablets in the treatment of chronic bacterial prostatitis. Methods A prospective, retrospective randomized controlled clinical trial was conducted in which 39 cases of chronic bacterial prostatitis were treated with cefixime and 42 cases were treated with sparfloxacin. Results The experimental group cured 32 cases (82.1%), while the control group cured 28 cases (66.7%). There were no adverse reactions in the experimental group, 7 cases (16.7%) in the control group, no significant difference between the two groups in the cure rate and the effective rate (P> 0.05), and the difference in adverse reactions was statistically significant (P <0.05). Conclusions The clinical efficacy of cefixime in the treatment of bacterial prostatitis is comparable to that in the control group (sparfloxacin group), while the adverse reaction is significantly lower than that in the control group, which is worthy of clinical application.